Chronic Hypertension in Pregnancy: What Timing Decides
Two women carry the same diagnosis into the same trimester from different starting points. One is already on a drug that's safe to keep and the only question is how tightly to control it. The other is already exposed to a drug that wasn't, and nothing about today's visit can undo that.
R.T., a 32-year-old woman, is nine weeks into her first pregnancy. She has kept up the same early-morning running routine she started three years ago, not long after a routine work physical first turned up blood pressure numbers her primary care doctor didn't like — four or five miles most mornings, rain or shine, a habit that turned out to double as blood pressure management well before she thought of it that way. Ambulatory monitoring at the time confirmed sustained hypertension rather than a single elevated reading, and labetalol brought her numbers into a comfortable range within a few weeks; she has been on the same 200 mg twice-daily dose ever since, with no diabetes, no kidney disease, and no prior pregnancy complications to complicate the picture. Her home blood pressure log for the past three weeks — kept with the same discipline that gets her out the door before sunrise — clusters between 134 and 142 systolic and 84 to 90 diastolic, numbers that would have drawn no particular comment from an obstetrician five years ago and draw a genuine argument today.
The argument is the 2022 Chronic Hypertension and Pregnancy trial — CHAP, as it's typically cited — which found that treating chronic hypertension to a target below 140/90 reduced the combined rate of severe preeclampsia, early preterm birth, and placental complications, and did so without the increase in SGA (small-for-gestational-age) infants that earlier guidance had worried tighter control would produce. That finding reversed a standing practice: obstetric teaching had generally held off intensifying treatment until blood pressure crossed a much higher threshold, out of concern that lowering maternal pressure further would reduce blood flow across the placenta rather than protect it. R.T.'s numbers sit close enough to the new target, and far enough from the old one, that where a given clinician trained shapes how urgently the case reads — and pregnancy's own pharmacokinetics complicate the picture further, since labetalol's hepatic clearance tends to rise as pregnancy progresses, meaning a dose that looks adequate at nine weeks may quietly stop being adequate by the third trimester regardless of which target philosophy wins today's conversation.
Setting a target for a patient already close to it
Her diastolic is already touching 90 on more than half her home readings, and CHAP is about as clean a signal as obstetric pharmacology gets — treat to below 140/90 and you cut severe preeclampsia and early preterm birth without the growth-restriction penalty everyone used to worry about. I'd increase the labetalol today rather than wait for a recheck to confirm what three weeks of home readings have already shown.
I'd have made the opposite argument five years ago, before the trial existed. That's not a criticism of anyone who trained under the old threshold — it's exactly what the evidence has since moved past.
I've read the same trial, and I'd point out that CHAP's own treated group landed at a mean around 130 over 79 — well under target, not hovering at the edge of it the way R.T. is. Most of her systolic readings are still under 140; it's really the diastolic that's borderline. Uptitrating labetalol isn't free — dizziness and fatigue are common enough at higher doses that a healthy, active 32-year-old might reasonably prefer two more weeks of monitoring before we commit to a dose she may not need.
I'm not arguing against the trial. I'm arguing that a mean achieved-BP well under target in the trial population doesn't automatically mean every patient near the threshold needs the same dose increase to get the same benefit.
Both of those are true, and neither one settles it alone — so here's a version that doesn't require picking a side on the target question. Labetalol undergoes extensive first-pass glucuronidation, and pregnancy increases both plasma volume and hepatic clearance as it progresses, which means her current dose is, if anything, more likely to become inadequate than excessive as she moves toward the third trimester, independent of whatever we decide about today's numbers specifically. A modest increase now, with a two-week recheck, treats the trend she's already on rather than treating either the CHAP target or the wait-and-see position as an abstract commitment.
Agreed within the visit: increase labetalol to 300 mg twice daily, start low-dose aspirin at 12 weeks for preeclampsia prophylaxis given her chronic hypertension, and recheck her home blood pressure log in two weeks.
Also agreed, rather than left open the way the target debate might suggest, is what happens at that recheck:
The plan holds as written and no additional agent is added.
Nifedipine ER is added at the recheck visit itself, rather than waiting for a second appointment to make that call.
The disagreement about how urgently CHAP's target applies to a patient this close to the line didn't get resolved so much as made beside the point — pregnancy's own pharmacokinetics gave both sides a reason to increase the dose today, even though they would have kept arguing about timing if that argument hadn't been available.
M.O., a 29-year-old woman, is seven weeks into a pregnancy she hadn't been planning quite yet. She'd told her cardiologist six months ago that she wanted to switch off lisinopril before trying to conceive, and the appointment to actually do it kept sliding — a demanding stretch at work, a rescheduled visit, the ordinary way a plan that isn't urgent yet stops being a priority — until a positive home pregnancy test ten days ago made it urgent all at once. She has been on lisinopril 20 mg daily for two years, since chronic hypertension diagnosed at a routine visit, and otherwise has no diabetes, no chronic kidney disease, and this is her first pregnancy. She stopped the medication the same day the test came back positive and called her cardiologist directly, who referred her for an urgent visit rather than waiting for her next scheduled appointment.
By the time she's seen, the lisinopril exposure is already complete — it ran to about five and a half weeks of gestation, the day she stopped, and nothing about today's visit changes that fact. What it can change is how the exposure gets read. The fetopathy ACE inhibitors are best known for — oligohydramnios, renal dysgenesis, skull ossification defects — depends on the fetal kidneys actually producing urine into the amniotic fluid, a function the fetal renin-angiotensin system (RAS) doesn't take on in earnest until the second trimester; exposure that stops before then, as hers did, isn't expected to produce that specific injury. But a 2006 cohort study found an association between first-trimester-only ACE inhibitor exposure and a different problem entirely — cardiac and central nervous system malformations, arising from a much earlier developmental window than the classic fetopathy — and that finding, unlike the fetopathy mechanism, has never been fully settled.
Reading an exposure that's already over
The mechanism you'd worry about first — renal dysgenesis, oligohydramnios, the fetopathy every pharmacology course teaches — depends on fetal urine output into the amniotic fluid, and the fetal RAS isn't driving that in any meaningful way until the second trimester. She stopped seven weeks in. Mechanistically, that specific injury shouldn't be on the table for this pregnancy.
That's the fetopathy mechanism, and I agree it's not in play here. But Cooper's 2006 cohort found something else — major cardiac and CNS malformations tied specifically to first-trimester-only exposure, a different developmental window and a different injury than the one you just ruled out. I'd want a detailed anatomy scan and a fetal echocardiogram, not just the standard scan, given that signal.
It's a large enough effect size in that cohort that I don't think it's responsible to wave it off as noise, even with the mechanism unclear.
I'd slow down before ordering the echo reflexively. The cohorts that raised that signal couldn't fully separate the drug's effect from the fact that women who need antihypertensive treatment before conception already carry other risk factors — the underlying hypertension itself, and often undiagnosed diabetes — that independently raise congenital malformation risk. Later analyses that tried to adjust for that found the excess risk attenuates substantially. I'd get the standard detailed anatomy scan everyone in this position gets, and reserve the echo for if that scan shows anything equivocal, rather than ordering it up front on a signal this contested.
Agreed immediately, and never actually contested: lisinopril stays stopped, methyldopa starts today, and low-dose aspirin begins at 12 weeks for the same preeclampsia risk her chronic hypertension carries regardless of which drug controls it.
Not agreed, and not likely to resolve before her anatomy scan, is how much additional surveillance the completed exposure itself warrants:
A fetal echocardiogram gets scheduled alongside the standard anatomy scan, rather than waiting to see if anything looks equivocal first.
The standard anatomy scan is enough on its own, and an echocardiogram is added only if that scan gives a reason to look further.
Nobody in the room thought the other position was unreasonable — the disagreement tracks a real, unresolved question in the literature itself, not a gap in anyone's reading of it. M.O. leaves the visit with a plan for the drug and an open question about the scan that her anatomy ultrasound, still eleven weeks away, will settle in practice before anyone settles it in principle.